Multi-center, Investigator Initiated Phase 1 Study of NY-ESO-1 Specific TCR Gene Transduced T Lymphocytes Transfer for Patients with Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 18 Aug 2017
At a glance
- Drugs NTBI 1301 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Takara Bio
- 31 Jul 2017 Planned End Date changed from 31 Mar 2017 to 31 Mar 2018.
- 31 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 07 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.